Martin Kozicki

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial

G. Shapiro, P. Ravindran, J. Diamond, 2022, Cancers.

393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results

P. Ascierto, D. Davar, P. Ravindran, 2020 .

Roles of DNA Damage Response Proteins in Mitogen-Induced Thp-1 Differentiation into Macrophage.

T. Ouchi, E. So, Martin Kozicki, 2013, Journal of cancer biology & research.